e-learning
resources
London 2016
Tuesday, 06.09.2016
Preclinical pharmacology: drug targets and mechanisms of action
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
MUC1-CT mediates corticosteroid responses in COPD
Lucia Diaz (A coruña, Spain), Lucia Diaz, Javier Milara, Esteban Morcillo, Adela Serrano, Ricardo Guijarro, Celia Sanz, Julio Cortijo
Source:
International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action
Session:
Preclinical pharmacology: drug targets and mechanisms of action
Session type:
Thematic Poster
Number:
4095
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Lucia Diaz (A coruña, Spain), Lucia Diaz, Javier Milara, Esteban Morcillo, Adela Serrano, Ricardo Guijarro, Celia Sanz, Julio Cortijo. MUC1-CT mediates corticosteroid responses in COPD. Eur Respir J 2016; 48: Suppl. 60, 4095
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Evidence-based eHealth for COPD
Related content which might interest you:
Irisin is associated with severe exacerbations of COPD independently of lung function, comorbidities and exercise capacity
Source: International Congress 2015 – Notable abstracts in COPD: variety
Year: 2015
Symptom profile of exacerbations in earlier and later COPD
Source: Annual Congress 2013 –Asthma and COPD: diseases with different phenotypes
Year: 2013
Do inhaled corticosteroids reduce the frequent exacerbator phenotype in COPD - A little help by a multicenter survey
Source: International Congress 2016 – Biomarkers and phenotypes of COPD
Year: 2016
Clinical and inflammatory characteristics of 'unreported' COPD exacerbations
Source: Annual Congress 2013 –COPD mechanisms
Year: 2013
Increased circulating alveolar epithelial microparticles in COPD patients
Source: International Congress 2015 – Modulating the immune system in COPD and asthma
Year: 2015
Comparative study of hospitalized patients with acute exacerbation of COPD with and without carbon dioxide retention
Source: Annual Congress 2013 –COPD treatment and others
Year: 2013
IL-17A is specifically elevated in NTHi-associated AECOPD and end-stage COPD
Source: International Congress 2015 – Modulating the immune system in COPD and asthma
Year: 2015
Altered expression of glycosaminoglycans in the BAL of COPD patients with acute exacerbation
Source: Annual Congress 2013 –Translational studies in chronic lung diseases: from bedside to bench
Year: 2013
The role of IFN-γ in severe COPD patients with anamnestic viral-induced exacerbations before and after roflumilast treatment
Source: International Congress 2016 – Translational studies in lung disease
Year: 2016
RT protocol reduces AECOPD readmissions
Source: International Congress 2016 – In-patient and out-patient COPD management
Year: 2016
COPD exacerbation: Influence of severity and type of systemic inflammation on the hospitalizations rate
Source: International Congress 2015 – COPD: chronic disease and comorbidities
Year: 2015
The serum level of surfactantproteind in patients with chronic obstructive pulmonary disease, depending on the nutrtional status
Source: International Congress 2015 – Notable abstracts in exacerbations, mechanisms and biomarkers in COPD
Year: 2015
QVA149 reduces COPD exacerbation rate in various subgroups of patients: The SPARK study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013
CAT in COPD phenotypes (POPE study)
Source: International Congress 2016 – Phenotyping and monitoring airway diseases
Year: 2016
Frequency of COPD exacerbations and severity of COPD
Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations
Year: 2013
The bronchitic phenotype is associated with frequent exacerbations in COPD irrespective of chronic bacterial airway infection
Source: Annual Congress 2013 –Guidelines and exacerbations
Year: 2013
A pilot study of CPAP therapy for excessive dynamic airway collapse during acute exacerbation of COPD
Source: International Congress 2014 – COPD - from biomarkers to novel therapeutic opportunities
Year: 2014
FEV1 decline in patients with chronic obstructive pulmonary disease: Which treatment option is better for slowing of decline?
Source: International Congress 2015 – COPD: exacerbations, gas exchange and associated dysfunction
Year: 2015
Are there any differences between Tunisian and European COPD phenotypes?
Source: International Congress 2016 – Best abstracts in COPD management
Year: 2016
COPD on anti-GERD therapy remains at higher risk for severe exacerbation
Source: International Congress 2014 – COPD exacerbations
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept